Ziprasidone in the treatment of mania in bipolar disorder

Stephen E Nicolson1, Charles B Nemeroff21From the Department of Psychiatry, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA; 2From the Department of Psychiatry and Behavioral Sciences, Emory University, School of Medicine, Atlanta, GA, USAAbstract: Ziprasidone is an at...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stephen E Nicolson, Charles B Nemeroff
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2007
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/b055fab85fe44194af5e73f339ed9a26
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b055fab85fe44194af5e73f339ed9a26
record_format	dspace
spelling	oai:doaj.org-article:b055fab85fe44194af5e73f339ed9a262021-12-02T07:33:10ZZiprasidone in the treatment of mania in bipolar disorder1176-63281178-2021https://doaj.org/article/b055fab85fe44194af5e73f339ed9a262007-01-01T00:00:00Zhttp://www.dovepress.com/ziprasidone-in-the-treatment-of-mania-in-bipolar-disorder-a960https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Stephen E Nicolson1, Charles B Nemeroff21From the Department of Psychiatry, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA; 2From the Department of Psychiatry and Behavioral Sciences, Emory University, School of Medicine, Atlanta, GA, USAAbstract: Ziprasidone is an atypical antipsychotic with a unique receptor-binding profile. Currently, ziprasidone is approved by the US Food and Drug Administration for the acute treatment of psychosis in schizophrenia and mania in bipolar disorder. When compared to certain other atypical antipsychotics, ziprasidone appears to have a relatively benign side effect profile, especially as regards metabolic effects eg, weight gain, serum lipid elevations and glucose dysregulation. Taken together, these data suggest that ziprasidone may be a first line treatment for patients with bipolar mania. However, ziprasidone is a relatively new medication for which adverse events after long-term use and/or in vulnerable patient populations must be studied. Unstudied areas of particular importance include the efficacy and safety of ziprasidone in the treatment of bipolar depression and relapse prevention of mania as, well as in the subpopulations of pregnant women, the elderly and pediatric patients. The emergence of mania in patients taking ziprasidone is another topic for further study.Keywords: antipsychotic, bipolar disorder, mania, mood disorder, neuroleptic, ziprasidone Stephen E NicolsonCharles B NemeroffDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2007, Iss Issue 6, Pp 823-834 (2007)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Stephen E Nicolson Charles B Nemeroff Ziprasidone in the treatment of mania in bipolar disorder
description	Stephen E Nicolson1, Charles B Nemeroff21From the Department of Psychiatry, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA; 2From the Department of Psychiatry and Behavioral Sciences, Emory University, School of Medicine, Atlanta, GA, USAAbstract: Ziprasidone is an atypical antipsychotic with a unique receptor-binding profile. Currently, ziprasidone is approved by the US Food and Drug Administration for the acute treatment of psychosis in schizophrenia and mania in bipolar disorder. When compared to certain other atypical antipsychotics, ziprasidone appears to have a relatively benign side effect profile, especially as regards metabolic effects eg, weight gain, serum lipid elevations and glucose dysregulation. Taken together, these data suggest that ziprasidone may be a first line treatment for patients with bipolar mania. However, ziprasidone is a relatively new medication for which adverse events after long-term use and/or in vulnerable patient populations must be studied. Unstudied areas of particular importance include the efficacy and safety of ziprasidone in the treatment of bipolar depression and relapse prevention of mania as, well as in the subpopulations of pregnant women, the elderly and pediatric patients. The emergence of mania in patients taking ziprasidone is another topic for further study.Keywords: antipsychotic, bipolar disorder, mania, mood disorder, neuroleptic, ziprasidone
format	article
author	Stephen E Nicolson Charles B Nemeroff
author_facet	Stephen E Nicolson Charles B Nemeroff
author_sort	Stephen E Nicolson
title	Ziprasidone in the treatment of mania in bipolar disorder
title_short	Ziprasidone in the treatment of mania in bipolar disorder
title_full	Ziprasidone in the treatment of mania in bipolar disorder
title_fullStr	Ziprasidone in the treatment of mania in bipolar disorder
title_full_unstemmed	Ziprasidone in the treatment of mania in bipolar disorder
title_sort	ziprasidone in the treatment of mania in bipolar disorder
publisher	Dove Medical Press
publishDate	2007
url	https://doaj.org/article/b055fab85fe44194af5e73f339ed9a26
work_keys_str_mv	AT stephenenicolson ziprasidoneinthetreatmentofmaniainbipolardisorder AT charlesbnemeroff ziprasidoneinthetreatmentofmaniainbipolardisorder
_version_	1718399358526816256

Ziprasidone in the treatment of mania in bipolar disorder

Ejemplares similares